Moxetumomab pasudotox 产品活性：Moxetumomab pasudotox (CAT 8015) 是一种抗 CD22 免疫毒素，含有抗 CD22 Fv 和 Pseudomonas exotoxin。CD22 是在多种恶性 B 细胞上表达的细胞表面受体。Moxetumomab pasudotox 可用于毛细胞白血病 (HCL) 的研究。 产品来源： https://www.medchemexpress.cn/moxetumomab-pasudotox.html 研究领域：Antibody-drug Conjugate/ADC Related | Immunology/Inflammation 作用靶点：Antibody-Drug Conjugates (ADCs) | CD22 In Vitro: Moxetumomab pasudotox (0-10 mg/mL, 66 h) reduces cell viability of BCP-ALL cells (determined by Annexin-V negative). The binding and internalization of MP/CD22 complexes is correlated with pre-B ALL cell line responses to MP. In Vivo: Moxetumomab pasudotox (300 mg/kg, i.v., every other day) prolongs median survival in 697 cell model (P Moxetumomab pasudotox (0.4 mg/kg, i.v. three doses, every other day) clears the bone marrow (BM) from acute lymphoblastic leukemia (ALL), but disease relapses from discrete BM-sites in NSG mouse model. 相关产品：Trastuzumab deruxtecan | Trastuzumab emtansine | Sacituzumab govitecan | Disitamab vedotin | Datopotamab deruxtecan | Brentuximab vedotin | Enfortumab vedotin-ejfv | Gemtuzumab ozogamicin | Patritumab deruxtecan | Mirvetuximab soravtansine (solution) | Belantamab mafodotin | Telisotuzumab vedotin | Tusamitamab ravtansine | Polatuzumab vedotin | Labetuzumab govitecan | Loncastuximab tesirine | Tisotumab vedotin | Inotuzumab | ANG1005 | Epratuzumab | Farletuzumab ecteribulin | Glembatumumab vedotin | Trastuzumab duocarmazine | Cantuzumab ravtansine | Cofetuzumab pelidotin 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。